(Date:10/13/2008)...ave Higher Sensitivity and Specificity, than Othe...he preferred test in all phases of...- AT First Diagnostic LLC an,emerging...st kits, today,announced that a recent evaluation ...earch of the FirstVue(TM) HBSAG Test, was released...
(Date:10/13/2008)...tiple Cancer Populations Facilitates ...Oct. 13 /- Rubicon Genomics, Inc. tod...mplify DNA samples for The,Cancer Atlas Genome Pro...nd standardize total genomic,DNA from 3,000 tissue...on,GenomePlex(TM) Whole Genome Amplification techn...
(Date:10/12/2008)...in Combination with Chemotherapy, FREMONT, Calif....c., a,development-stage pharmaceutical company dis...Ai)-based therapeutics, today announced that the,j...cy of siRNA targeting,its proprietary target gene ...edition dated October 1, 2008. The paper, entitled...
(Date:10/12/2008)...t. 12 /- Boston,Scientific ...from an analysis,of nearly 7,500 patients from its...ed to confirm the performance of the TAXUS(R) Expr...in real-world practice. The,two-year pooled ARRIVE...,restenosis in patients with diabetes as effective...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Previously unseen switch regulates breast cancer response to estrogen 18812 1Previously unseen switch regulates breast cancer response to estrogen 18812 2Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 1Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 1Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 3...akthrough Will Aid in Developing Therapies to Prev...RYVILLE, Calif., May 10, 2007 /PRNewswire/ -- Kine...lopment company, announced,today the first method ...es in animals through the pathway known as reverse...n mechanism by which excess,cholesterol can be rem...
...POLIS, France, May 11, 2007 /PRNewswire-FirstCall/...pdate on the phase 2a,study for NCX 1000, which is... Pharma Inc. A preliminary analysis of 11 patient...tension confirmed,the safety profile of NCX 1000 b...pport the continuation of this clinical trial. As ...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: